Parkinson disease and growth factors — is GDNF good enough?

Research output: Contribution to journal › Comment/debate › Research › peer-review

Standard

Parkinson disease and growth factors — is GDNF good enough? / Kirkeby, Agnete; Barker, Roger A.

In: Nature Reviews Neurology, Vol. 15, No. 6, 01.06.2019, p. 312-314.

Research output: Contribution to journal › Comment/debate › Research › peer-review

Harvard

Kirkeby, A & Barker, RA 2019, 'Parkinson disease and growth factors — is GDNF good enough?', Nature Reviews Neurology, vol. 15, no. 6, pp. 312-314. https://doi.org/10.1038/s41582-019-0180-6

APA

Kirkeby, A., & Barker, R. A. (2019). Parkinson disease and growth factors — is GDNF good enough? Nature Reviews Neurology, 15(6), 312-314. https://doi.org/10.1038/s41582-019-0180-6

Vancouver

Kirkeby A, Barker RA. Parkinson disease and growth factors — is GDNF good enough? Nature Reviews Neurology. 2019 Jun 1;15(6):312-314. https://doi.org/10.1038/s41582-019-0180-6

Author

Kirkeby, Agnete ; Barker, Roger A. / Parkinson disease and growth factors — is GDNF good enough?. In: Nature Reviews Neurology. 2019 ; Vol. 15, No. 6. pp. 312-314.

Bibtex

@article{765e479cce1141c7a299dd3df9acc737,
title = "Parkinson disease and growth factors — is GDNF good enough?",
abstract = "Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.",
author = "Agnete Kirkeby and Barker, {Roger A.}",
year = "2019",
month = jun,
day = "1",
doi = "10.1038/s41582-019-0180-6",
language = "English",
volume = "15",
pages = "312--314",
journal = "Nature Reviews. Neurology",
issn = "1759-4758",
publisher = "nature publishing group",
number = "6",

}

RIS

TY - JOUR

T1 - Parkinson disease and growth factors — is GDNF good enough?

AU - Kirkeby, Agnete

AU - Barker, Roger A.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.

AB - Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.

UR - http://www.scopus.com/inward/record.url?scp=85064011594&partnerID=8YFLogxK

U2 - 10.1038/s41582-019-0180-6

DO - 10.1038/s41582-019-0180-6

M3 - Comment/debate

C2 - 30948845

AN - SCOPUS:85064011594

VL - 15

SP - 312

EP - 314

JO - Nature Reviews. Neurology

JF - Nature Reviews. Neurology

SN - 1759-4758

IS - 6

ER -

ID: 228505366